On June 23, 2025, Genprex, Inc. reported positive preclinical findings for its diabetes gene therapy drug candidate GPX-002, presented at the 2025 American Diabetes Association meeting, using a non-viral lipid nanoparticle delivery system. This research could allow repeated dosing for Type 1 diabetes treatment, showing promising results with specific lipid nanoparticles in transfecting mouse pancreatic cells.